Nanoencapsulated Curcumin: Enhanced Efficacy in Reversing Memory Loss in An Alzheimer Disease Model

• Published in: Brain sciences 2024-02, Vol.14 (2), p.130
• Main Authors: Savall, Anne Suély Pinto, de Mello, Jhuly Dorneles, Fidelis, Eduarda Monteiro, Comis-Neto, Antonio Alvenir, Nepomuceno, Maria Regina, Pacheco, Camila de Oliveira, Haas, Sandra Elisa, Pinton, Simone
• Format: Article
• Language: English
• Subjects: Acetylcholinesterase; Advertising executives; Alzheimer's disease; Animal cognition; Animal models; Curcumin; Drug therapy; Glial fibrillary acidic protein; Health aspects; Inflammation; Memory; nanotechnology; Neurodegenerative diseases; neuroinflammation; Oxidative stress; Pattern recognition; Permeability; Streptozocin; streptozotocin; Target marketing; Therapeutic applications
• ISSN: 2076-3425; 2076-3425
• DOI: 10.3390/brainsci14020130

Investigating new drugs or formulations that target Alzheimer disease (AD) is critical for advancing therapeutic interventions. Therefore, this study aimed to assess the effectiveness of nanoencapsulated curcumin (NC Curc) in alleviating memory impairment, oxidative stress, and neuroinflammation in a validated AD model. Male Wistar rats were given bilateral intracerebroventricular injections of either saline or streptozotocin (STZ) (3 mg/3 µL/site) to establish the AD model (day 0). On day 22, daily oral administrations of curcumin (6 mg/kg), NC Curc (6 mg/kg), or a vehicle (unloaded NC) were initiated and continued for 14 days. NC Curc significantly reversed memory deficits in object recognition and inhibitory avoidance tests induced by STZ. Both formulations of curcumin attenuated elevated acetylcholinesterase activity caused by STZ. Importantly, NC Curc alone effectively mitigated STZ-induced oxidative stress. Additionally, NC Curc treatment normalized GFAP levels, suggesting a potential reduction in neuroinflammation in STZ-treated rats. Our findings indicate that NC Curc improves memory in an AD rat model, highlighting its enhanced therapeutic effects compared to unencapsulated curcumin. This research significantly contributes to understanding the therapeutic and neurorestorative potential of NC Curc in AD, particularly in reversing pathophysiological changes.